Camibirstat clinical trials
Also written FHD-286.
How each study uses camibirstat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the camibirstat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- FHD-286
- 5
Studies by the year they started
5 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 3
Foghorn Therapeutics Inc. (2) · Weill Medical College of Cornell University (1) · Dana-Farber Cancer Institute (1) · Montefiore Medical Center (1)
Studies
Open first, then newest update. How each study uses camibirstat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Trial of FHD-286 Plus Mosunetuzumab in Previously Treated Follicular LymphomaNot yet recruitingPhase 1Weill Medical College of Cornell UniversityNCT07941492Written as FHD-286How we know
- SMARCA4/2 Inhibitor for POU2F3-Positive SCLCRecruitingPhase 2Dana-Farber Cancer InstituteNCT07551635Written as FHD-286How we know
- FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid LeukemiaRecruitingPhase 1Montefiore Medical CenterNCT07283094Written as FHD-286How we know
- FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic MalignanciesActive, not recruitingPhase 1Foghorn Therapeutics Inc.NCT04891757Written as FHD-286How we know
- FHD-286 in Subjects With Metastatic Uveal MelanomaTerminatedPhase 1Foghorn Therapeutics Inc.NCT04879017Written as FHD-286How we know
What changed recently
From the registry's own updates since Oct 23, 2026.
Started recruiting1
- SMARCA4/2 Inhibitor for POU2F3-Positive SCLCOct 26, 2026NCT07551635
Newly registered1
- A Trial of FHD-286 Plus Mosunetuzumab in Previously Treated Follicular LymphomaNov 17, 2026NCT07941492
Codes
What other systems call camibirstat · ClinicalTrials.gg INT017688
- UNII (FDA) QHA5XLA4SACAMIBIRSTATOne source FDA
- NCI Thesaurus C179408CamibirstatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | QHA5XLA4SA | CAMIBIRSTAT | One source FDA |
| NCI Thesaurus | C179408 | Camibirstat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.